Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Study on the prognostic impact of interferon-gamma-inducible protein 16 level in multiple myeloma patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • نبذة مختصرة :
      المقال يركز على التأثير التنبؤي لمستويات بروتين 16 القابل للتحفيز بواسطة إنترفيرون غاما (IFI-16) في مرضى المايلوما المتعددة (MM). أظهرت دراسة شملت 30 مريضًا تم تشخيصهم حديثًا بالمايلوما المتعددة و30 شخصًا سليمًا أن مستويات IFI-16 المرتفعة في المصل كانت مرتبطة بشكل كبير بمراحل المرض المتقدمة وعوامل التنبؤ السلبية، مثل زيادة مستويات الكرياتينين في المصل وإنزيم اللاكتات ديهيدروجيناز. تشير الأبحاث إلى أن مستوى قطع IFI-16 الذي يزيد عن 1.43 نانوغرام/مل يمكن أن يميز بفعالية بين مرضى المايلوما المتعددة والأفراد الأصحاء، وأن مستويات IFI-16 الأعلى ترتبط ببقاء خالٍ من المرض (DFS) لفترة أقصر. تشير النتائج إلى أن قياس IFI-16 قد يكون مفيدًا في التنبؤ بالانتكاسة وتوجيه استراتيجيات العلاج لمرضى المايلوما المتعددة. [Extracted from the article]
    • نبذة مختصرة :
      Background: Interferon-gamma-inducible protein 16 (IFI-16) is a member of the pyrin and hematopoietic interferon-inducible nuclear domain 200 gene family, which modulates proliferation, survival as well as various cell lineage differentiation. Recent studies have shown that IFI-16 predicts prognosis in many cancers as enhanced IFI-16 expression was linked to favorable prognosis of hematological malignancies, involving chronic lymphocytic leukemia and mantle cell lymphoma. Aim: To investigate IFI-16 serum levels as a diagnostic and prognostic marker for newly diagnosed multiple myeloma (MM) cases. Patients and methods: Our prospective study involved 30 newly diagnosed MM cases and 30 healthy volunteers. Serum IFI-16 was measured using the enzyme-linked immunosorbent assay. Results: The IFI-16 level exhibited a significant increase among the patient's group compared with the control group. It was significantly increased within stage III compared with stages I and II, and in relapsed cases compared with nonrelapsed cases. IFI-16 was significantly positively correlated with serum creatinine, lactate dehydrogenase enzyme, β2 microglobulin, and serum calcium while negatively correlated with serum albumin. IFI-16 at a cutoff more than 1.43 ng/ml can significantly differentiate MM cases from controls. IFI-16 was significantly associated with disease-free survival (DFS) in both univariate and multivariate analyses, and patients with high IFI-16 had a shorter DFS compared with those with low IFI-16. Conclusion: Our study concluded that a high level of IFI-16 was associated with advanced myeloma staging, and correlated with negative prognostic markers such as β2 microglobulin, lactate dehydrogenase, serum calcium, creatinine, and albumin, which are linked to greater relapse rate as well as shorter DFS. [ABSTRACT FROM AUTHOR]
    • نبذة مختصرة :
      Copyright of Egyptian Journal of Haematology is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)